 |
| Weekly Journal Scans | More » |
 |
Reduced-Intensity Conditioning With Allo-SCT in Patients With Myelofibrosis
Blood, 2009 Oct 7, N Kroger, et al
Older age and donor-HLA mismatch adversely affected survival of patients treated with reduced-dose conditioning and SCT.
|
AML1/RUNX1 Mutations Are Prognostic in AML
Blood, 2009 Oct 6, J-L Tang, et al
RUNX1 mutation was an independent prognostic factor for poor overall survival in patients with de novo AML.
|
Curative Surgery in Metastatic CRC Treated With Bevacizumab
Br J Cancer, 2009 Oct 6, A Okines, et al
Two studies evaluated the safety and survival effect of bevacizumab in patients undergoing surgery for metastatic colorectal cancer.
|
Casopitant Is Beneficial for Chemotherapy-Related Nausea and Vomiting
J Clin Oncol, 2009 Oct 5, J Herrstedt, et al
Casopitant plus ondansetron and dexamethasone was safe and effective in preventing chemotherapy-induced nausea and vomiting.
|
Prognostic Significance of AFP in Hepatocellular Carcinoma
J Clin Oncol, 2009 Oct 5, A Riaz, et al
AFP response was a prognostic indicator for radiologic tumor response and OS in patients receiving locoregional therapy for HCC.
|
Satraplatin Plus Prednisone in Castrate-Refractory Prostate Cancer
J Clin Oncol, 2009 Oct 5, CN Sternberg, et al
Satraplatin plus prednisone demonstrated improved PFS, but not OS, in men with progressive disease after initial chemotherapy.
|
Cost-Effectiveness of Trastuzumab in HER2-Positive Metastatic Breast Cancer
Am J Clin Oncol, 2009 Oct 1, C Perez-Ellis, et al
Longer OS but higher treatment costs with trastuzumab still translated into positive cost-effectiveness in a French analysis.
|
Venous Thromboembolism in Lymphoma: How Effectively Are We Treating Patients?
Am J Clin Oncol, 2009 Oct 1, AA Muslimani, et al
Warfarin treatment was linked with a 30% rate of recurrent thrombosis and a 13% rate of major bleeding in lymphoma patients.
|
Sentinel Lymph Node Surgery Before vs After Neoadjuvant Chemotherapy
Ann Surg, 2009 Oct 1, KK Hunt, et al
SLN surgery performed after chemotherapy, as opposed to before, is equally accurate for axillary staging.
|
Paclitaxel–Ifosfamide–Cisplatin (TIP) in Relapsed or Metastatic Cervical Cancer
Br J Cancer, 2009 Sept 8, C Kosmas, et al
Paclitaxel–ifosfamide–cisplatin (TIP) produced an ORR of 62% in patients with recurrent or metastatic cervical cancer.
|
Indwelling Catheters for the Management of Refractory Malignant Ascites
J Pain Symptom Manage, 2009 Sept 1, ND Fleming, et al
Indwelling IP catheters are safe and effective in the palliative management of malignant ascites, and are not associated with overly high infection rates.
|
Rechallenge With Bortezomib in Progressive Multiple Myeloma
Am J Hematol, 2009 Jul 30, R Sood, et al
Previous responders to bortezomib achieve responses upon re-treatment for relapsed multiple myeloma.
|
|
| | |
| ECCO/ESMO 2009
Conference news plus interviews with ECCO/ESMO officers.
| |
|
|
| | |
| CANCER POLICY FORUM
Get behind-the-headline perspectives on the politics of cancer.
VISIT SITE
| |
|
|
| | |
| WHEN THE SMOKE CLEARS
Experts discuss the true clinical implications of watershed developments in oncology research.
VISIT SITE
| |
|
|
| | |
| RELATED WEBSITES
These websites offer more information on a variety of oncology-related topics.
VISIT SITE
| |
|
|
| | |
| VIDEOS
Watch video interviews with leading cancer experts.
VISIT SITE
| |
|
|
|
A Week in Review